Hardman Johnston Global Advisors LLC Has $24.77 Million Stake in IQVIA Holdings Inc. $IQV

Hardman Johnston Global Advisors LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,907 shares of the medical research company’s stock after selling 9,869 shares during the period. IQVIA accounts for 1.2% of Hardman Johnston Global Advisors LLC’s holdings, making the stock its 25th largest position. Hardman Johnston Global Advisors LLC’s holdings in IQVIA were worth $24,774,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. raised its position in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares in the last quarter. Westside Investment Management Inc. raised its position in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new position in IQVIA during the third quarter valued at approximately $30,000. Finally, Atlantic Union Bankshares Corp acquired a new position in IQVIA during the third quarter valued at approximately $36,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 0.1%

Shares of NYSE:IQV opened at $167.49 on Monday. The company has a fifty day moving average of $173.38 and a 200-day moving average of $204.31. The company has a market capitalization of $28.42 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.62 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IQV shares. UBS Group lowered their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research report on Friday, March 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a research report on Monday, February 23rd. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Morgan Stanley set a $240.00 price objective on shares of IQVIA in a research report on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $226.63.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.